$38.67▾ 0.15%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+13.6%year over year
Healthy
Revenue is growing at a steady pace.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Indivior Pharmaceuticals, Inc. 's earnings-quality signal is not available yet. Revenue is growing at a steady pace.
Key numbers
Valuation
EPS (TTM)$2.79
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin26.7%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$1.33B
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days2 articles
1 bullish1 neutral0 bearish
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.